Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according ...

As monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received a positive opinion from the ...

Janssen-Cilag International NV, a Johnson & Johnson company, received European Medicines Agency's Committee for Medicinal Products ...

Johnson & Johnson was founded over 125 years ... It was in 1961 that Belgium's Janssen Pharmaceutica N.V. joined the J&J Family of Companies. Its founder, Dr Paul Janssen, is recognised as one ...

In the early hours of September 14 2021, three men parked in a quiet car park in the southern English market town of Abingdon-on-Thames. The men, ret ...

Glencoe-Silver Lake grabs 1st-half lead to beat Wildcats in Wright County game. Other winners Friday: Litchfield, Montevideo, Melrose, Morris/CA, Dawson-Boyd, KMS, RCW, Minneota, CMCS, Benson and ...

Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb.

Steals: 16 (R.Johnson 6, Fulwiley 3, Edwards 2, Feagin 1, T.Johnson 1, Kitts 1, McDaniel 1, Paopao 1) Percentages: FG 50.000, FT .647.

SC amivantamab, in combination with LAZCLUZE, is recommended for adult patients with advanced NSCLC with epidermal growth ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental It can be tough to keep things interesting ...